VIR · Vir Biotechnology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $68.56M | $74.20M | $86.18M | $1.62B | $1.10B | $76.37M |
| Cost of Revenue | $26.0K | $845.0K | $2.77M | $146.32M | $0 | - |
| Gross Profit | $68.53M | $73.36M | $83.42M | $1.47B | $1.10B | - |
| R&D | $455.97M | $506.50M | $589.67M | $474.65M | $448.01M | $302.41M |
| SG&A | $92.07M | $119.03M | $178.05M | $161.76M | $70.94M | $70.94M |
| Total Operating Expenses | $547.88M | $661.37M | $770.49M | $782.73M | $373.35M | $373.35M |
| D&A | $11.68M | $14.56M | $18.92M | $6.25M | $5.28M | $4.40M |
| Operating Income | ($479.33M) | ($587.16M) | ($684.30M) | $833.07M | $420.75M | ($296.98M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $217.0K | ($1.15M) | ($13.08M) | $238.44M | $21.22M | $54.0K |
| Net Income | ($437.99M) | ($521.96M) | ($615.12M) | $515.84M | $528.58M | ($298.67M) |
| EPS - Basic | ($3.16) | ($3.83) | ($4.59) | $3.89 | ($2.51) | - |
| EPS - Diluted | ($3.16) | ($3.83) | ($4.59) | $3.83 | ($2.51) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $232.19M | $222.95M | $241.58M | $848.63M | $347.81M | $436.57M |
| Accounts Receivable | - | - | - | $0 | $773.08M | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $9.80M | $5.08M | $6.33M | $6.42M | $6.52M | $5.08M |
| Current Assets | $514.08M | $1.04B | $1.59B | $2.52B | $1.56B | $772.37M |
| Total Assets | $1.00B | $1.40B | $1.92B | $2.80B | $1.95B | $918.76M |
| Current Liabilities | $92.81M | $119.66M | $175.41M | $511.03M | $341.24M | $99.06M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $237.55M | $248.43M | $328.82M | $724.13M | $522.42M | $201.91M |
| Stockholders' Equity | $765.28M | $1.15B | $1.59B | $2.08B | $1.43B | $716.85M |
| Retained Earnings | ($1.20B) | ($759.78M) | ($237.82M) | $377.24M | ($138.60M) | ($667.18M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($391.78M) | ($446.35M) | ($778.78M) | $1.66B | ($47.59M) | ($190.94M) |
| Investing Cash Flow | $310.37M | $499.37M | $164.63M | ($1.19B) | ($140.81M) | ($9.86M) |
| Financing Cash Flow | $3.79M | $4.39M | $7.48M | $34.76M | $100.33M | $529.47M |
| CapEx | $4.83M | $7.30M | $21.57M | $68.03M | $21.82M | $6.55M |
| Free Cash Flow | ($396.61M) | ($453.65M) | ($800.36M) | $1.60B | ($69.41M) | ($197.49M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 100.0% | 98.9% | 96.8% | 90.9% | 100.0% | - |
| Operating margin | -699.2% | -791.3% | -794.0% | 51.6% | 38.4% | -388.9% |
| EBITDA margin | -682.1% | -771.7% | -772.1% | 51.9% | 38.9% | -383.1% |
| Net margin | -638.9% | -703.4% | -713.8% | 31.9% | 48.3% | -391.1% |
| Free cash flow margin | -578.5% | -611.4% | -928.7% | 98.7% | -6.3% | -258.6% |
| FCF / Net income | 0.91 | 0.87 | 1.30 | 3.09 | -0.13 | 0.66 |
| R&D / Revenue | 665.1% | 682.6% | 684.2% | 29.4% | 40.9% | 396.0% |
| SG&A / Revenue | 134.3% | 160.4% | 206.6% | 10.0% | 6.5% | 92.9% |
| Effective tax rate | - | - | - | 31.6% | 3.9% | - |
| Return on assets | -43.7% | -37.3% | -32.1% | 18.4% | 27.0% | -32.5% |
| Return on equity | -57.2% | -45.4% | -38.7% | 24.8% | 36.9% | -41.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 | 7.80 |
| Quick ratio | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 | 7.80 |
| Cash ratio | 2.50 | 1.86 | 1.38 | 1.66 | 1.02 | 4.41 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.31 | 1.22 | 1.21 | 1.35 | 1.36 | 1.28 |
| Liabilities / Assets | 0.24 | 0.18 | 0.17 | 0.26 | 0.27 | 0.22 |
| Efficiency | ||||||
| Asset turnover | 0.07 | 0.05 | 0.04 | 0.58 | 0.56 | 0.08 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | 0d | 258d | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 137619d | 2195d | 836d | 16d | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | 6.6x | - | - |
| P / B | 1.1x | 0.9x | 0.8x | 1.6x | 3.5x | - |
| P / S | 12.2x | 13.5x | 15.7x | 2.1x | 4.6x | - |
| EV / EBITDA | - | - | - | 3.1x | 10.9x | - |
| Growth | ||||||
| Revenue growth (YoY) | -7.6% | -13.9% | -94.7% | 47.5% | 1334.4% | 2720.1% |
| Revenue CAGR (3y) | -65.1% | -59.2% | 4.1% | 741.9% | - | - |
| Revenue CAGR (5y) | -2.1% | 93.9% | - | - | - | - |
| Gross profit growth (YoY) | -6.6% | -12.1% | -94.3% | 34.1% | - | - |
| Operating income growth (YoY) | 18.4% | 14.2% | - | 98.0% | - | -264.4% |
| Net income growth (YoY) | 16.1% | 15.1% | - | -2.4% | - | -327.6% |
| EPS growth (YoY) | 17.5% | 16.6% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 12.6% | 43.3% | - | - | 64.9% | -185.7% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -33.5% | -27.7% | -23.5% | 45.1% | 99.7% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$68.56M totalReportable Segment$68.56M · 100.0%
Product / service
$67.42M totalLicense And Collaboration Revenue$63.13M · 93.6%
Other Revenue$3.39M · 5.0%
Grant$2.04M · 3.0%
Profit Sharing Amount($1.14M) · -1.7%
Geographic
$66.30M totalNon Us$64.27M · 96.9%
US$2.04M · 3.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-0.77
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Vir Biotechnology against the 5 most active filers in the same SIC group.